As demonstrated by ONWARDS findings, insulin icodec showed a comparable clinical efficacy profile with basal insulin analogues, in both T1DM and T2DM patients, regardless of whether patients had previously been treated with basal insulin or not. Here, INS is linked to type 1 diabetes mellitus.